 3. All subjects must have histologic evidence of G4 MG including glioblastoma and gliosarcoma and radiographic evidence of recurrence or disease progression defined as either a greater than 25 increase in the largest bidimensional product of enhancement, a new enhancing lesion, or significant increase in T2 FLAIR. 